Intestinal barrier dysfunction (“leaky gut”)

Intestinal barrier dysfunction, often called “leaky gut” in consumer marketing, means increased intestinal permeability: more luminal content crosses the gut wall (paracellular or transcellular) than is typical for health. The biology is real in celiac disease, active inflammatory bowel disease (IBD), subsets of irritable bowel syndrome (IBS), and some metabolic cohorts. What consumer panels usually show is microbial composition, not flux across the wall, and many zonulin ELISAs bundled with reports or sold separately do not reliably measure the protein they claim to detect (Massier et al., 2021).

This page separates anatomy and measurable permeability from wellness extrapolation. For how report lines map to concepts, start at Reading your microbiome report.

What not to conclude

Report or symptom pattern	Weak conclusion	More accurate framing
Low Faecalibacterium or “low butyrate pathway”	Proven leaky gut	Association with SCFA support in theory; does not measure permeability
Stool or serum zonulin flagged high	Confirmed barrier loss	Many ELISAs misidentify target proteins; validate assay before acting
Dysbiosis score	Barrier breakdown	Ecological deviation label, not a permeability assay
Bloating, fatigue, brain fog alone	Must be leaky gut	Non-specific; red flags and clinical workup first
Normal calprotectin	Barrier definitely intact	Calprotectin reflects inflammation, not direct leak measurement either
Gluten exclusion in non-celiac person	Automatically heals barrier	NCGWS permeability data are mixed; celiac pathway is distinct

When multiple conflicting lines appear on one panel, use Multi-marker report synthesis before stacking barrier supplements.

Is “leaky gut” real?

Claim	Evidence level (summary)
Intestinal permeability varies physiologically (meals, stress, exercise, menstrual cycle)	Supported
Permeability is measurably increased in celiac disease, active IBD, many IBS-D / post-infectious IBS cohorts, and some metabolic/obesity studies	Supported in defined populations
Low-grade LPS translocation (“metabolic endotoxemia”) occurs in some human obesity/metabolic studies	Supported as association; causality debated
Every person with bloating, fatigue, or brain fog has a clinically significant leaky gut	Not supported as a blanket diagnosis
Stool zonulin on a consumer panel proves permeability	Contradicted by assay validation studies

Better terminology for this site: prefer intestinal barrier dysfunction or increased intestinal permeability when discussing measurable biology; reserve “leaky gut” for quoting consumer language and explain the limits.

How the gut wall is structured

The barrier is multi-layered, not a single cell sheet.

Lumen
  ↓
【Mucus layer】          ← MUC2 gel (colon: inner + outer layers)
  ↓
【Epithelium】           ← Enterocytes, goblet cells, Paneth cells, immune cells
  ↓  Tight junctions between lateral borders
【Lamina propria】       ← Immune tissue, vessels, nerves
  ↓
Systemic circulation / mesenteric lymph

Small intestine vs colon

Region	Dominant barrier features
Small intestine	Single mucus layer (looser); huge surface area for absorption; primary site of most sugar-probe permeability tests
Colon	Two-layer MUC2 mucus, inner layer largely bacteria-free; outer layer hosts microbiota

Damage can occur at mucus, epithelial, or immune levels, not all “leaks” look the same on tests.

The epithelium and tight junctions (chemical view)

Enterocytes form a monolayer linked by tight junctions (TJs), multiprotein complexes at the apical lateral border.

Key TJ components

Protein family	Role (simplified)
Claudins	Form size-selective pores and seals; different claudins increase or decrease ion/solute passage
Occludin	TJ stability and signalling; not solely required for baseline barrier in all models
JAMs, tricellulin	Junction assembly and tricellular contacts
ZO-1, ZO-2	Scaffold proteins linking TJs to actin cytoskeleton

Regulation

TJs are dynamic. Inflammatory cytokines (TNF-α, IFN-γ), stress kinases (MLCK, ROCK), and bacterial products can redistribute claudins/occludin and open paracellular pathways. Butyrate and other SCFAs can support barrier gene expression in cell and animal models, human dose-response is context-dependent (see SCFAs).

Chemical size matters: probe tests use molecules of defined radius (e.g. mannitol ~4.3 Å vs lactulose ~~9 Å) to estimate small vs larger paracellular pathways.

The mucus layer and MUC2

In the colon, MUC2 mucin secreted by goblet cells forms a gel-like net expanded by hydration and post-secretory processing.

Two layers (classic model, Johansson/Hansson group)

Layer	Properties	Bacteria
Inner mucus	Dense, stratified, firmly attached	Largely absent in health
Outer mucus	Expanded, more permissive	Commensal habitat; glycan foraging

The inner layer is the critical physical shield preventing bacteria from contacting the epithelium. If bacteria reach the epithelium, immune activation and TJ modulation follow.

How the mucus layer is maintained

Continuous MUC2 secretion (including sentinel goblet cell pathways responsive to microbial cues)
Host protease/glycosidase processing converting inner → outer mucus
Microbial metabolism of mucin glycans in the outer layer only (in health)
SCFAs and CO₂/bicarbonate from fermentation influencing mucus expansion and structure
Dietary microbiota-accessible carbohydrates (MACs), low fiber can force mucus-degrading metabolism inward in animal models

Bacteria often discussed in barrier/mucus context

Organism / group	Typical framing	Nuance
Faecalibacterium prausnitzii	Butyrate producer; anti-inflammatory associations	Supports colonocyte metabolism; see species page
Bifidobacterium	Mucus-associated species; prebiotic responses	Helpful in some intervention studies; genus-level reporting hides strain effects
Akkermansia muciniphila	Mucin degrader; metabolic and barrier research focus	Degrades mucin but may support turnover in balance; not simply “good” or “bad”, see species page
Commensal mucin specialists (outer layer)	Normal in outer mucus	Problematic only if inner layer penetration occurs
Enteric pathogens (Salmonella, Citrobacter, etc.)	Mucus penetration, TJ disruption	Clear barrier injury
Proteolytic / mucolytic dysbiosis with low fiber	Animal models: mucus erosion when MACs scarce	Schroeder et al., fiber or Bifidobacterium protected mucus thickness in mice

Critical point: mucin degradation is physiological in the outer layer but pathological when the inner layer is breached or eroded.

Zonulin, mechanism vs biomarker

Biology

Zonulin refers to signalling via prehaptoglobin-2 (identified by Fasano’s group) that can disassemble tight junctions through PAR2/EGFR-linked pathways, increasing paracellular flux. Gliadin peptides can trigger zonulin release in celiac disease models, a cornerstone of the gluten–permeability link.

Biomarker controversy

Multiple independent groups report that widely used commercial zonulin ELISAs do not reliably measure prehaptoglobin-2, often detecting complement C3, properdin, or other proteins instead. These values poorly correlate with gold-standard permeability tests (e.g. lactulose–mannitol).

Implication for readers of test reports:

Serum or stool “zonulin” from standard ELISAs should not be interpreted as proof of leakiness until validated assays exist
This criticism does not negate all zonulin biology, it invalidates many published ELISA-based conclusions

See Zonulin on this site.

LPS and metabolic endotoxemia

Lipopolysaccharide (LPS) is a component of Gram-negative bacterial outer membranes. Normally, LPS exposure is largely luminal and handled by mucosal immunity.

When barrier function fails and/or bacterial load and translocation increase, LPS can enter circulation at low levels, metabolic endotoxemia (typically ~2–3× baseline in some obesity studies, not sepsis-level spikes).

Proposed cascade (mostly rodent + human association data)

High-fat diet / dysbiosis / TJ disruption (context-dependent)
        ↓
Increased LPS translocation
        ↓
TLR4/CD14 activation → TNF-α, IL-6, etc.
        ↓
Insulin resistance, hepatic inflammation, adipose inflammation (metabolic studies)
        ↓
Possible neuroimmune effects (see below)

LPS in blood is not a direct permeability test, it reflects translocation plus clearance plus immune response. Elevated LPS-binding protein (LBP) or soluble CD14 (sCD14) are research markers with similar limits.

Gluten and casein, what the literature actually supports

Gluten

Condition	Barrier evidence
Celiac disease	Strong: gliadin → zonulin pathway (research), increased permeability, reversible on gluten-free diet; anti-tissue transglutaminase (TTG) and biopsy are diagnostic anchors
Non-coeliac gluten / wheat sensitivity (NCGWS)	Barrier changes reported in subsets; mechanism not settled; not all studies replicate permeability findings
Healthy volunteers	Gliadin can trigger transient zonulin and permeability signals in some ex vivo / challenge models, magnitude and clinical relevance differ from celiac

Do not equate “gluten sensitivity” symptoms with celiac-level barrier injury without appropriate celiac serology and specialist workup.

Casein / dairy

Evidence for direct intestinal barrier disruption by casein in humans is weak compared with gluten in celiac disease.

Topic	Status
Lactose malabsorption	Osmotic diarrhoea and symptoms, not classic TJ “leak”
Cow’s milk allergy (IgE/non-IgE)	Immune-mediated gut injury in defined allergy, different mechanism
A1 vs A2 β-casein, β-casomorphin-7	Mostly animal, in vitro, or industry-associated reviews; hypothesized TLR/opioid and permeability effects, not established as clinical barrier diagnostics
Milk protein fractions (e.g. colostrum)	Small human trials in specific stress contexts (e.g. exercise-induced permeability, NSAID users), not general leaky-gut treatment evidence

Practical framing: dairy may worsen symptoms for intolerance/allergy reasons without proving a leaky gut.

What happens when the barrier fails?

Consequences depend on location, severity, and duration.

Local (gut)

Antigen sampling ↑ → immune activation in lamina propria
Diarrhoea, bleeding, mucosal inflammation in IBD/celiac
Visceral pain in IBS subsets linked to permeability and immune activation
Malabsorption when surface area and inflammation are severe

Systemic (when translocation occurs)

Low-grade inflammation, CRP, cytokines
Metabolic endotoxemia context, insulin resistance, NAFLD associations in research
Autoimmune disease hypotheses, celiac as model; broader “leaky gut causes autoimmunity” beyond celiac remains hypothesis-heavy
Liver: bacterial product load in cirrhosis (distinct pathology)

Neurological associations (brief)

Evidence that barrier dysfunction directly causes brain fog in the general population is thin. Acute LPS infusion studies show cytokine-linked mood and cognition changes in controlled settings, not the same as chronic consumer “leaky gut” framing. A specific D-lactic acidosis syndrome with brain fogginess has been reported with SIBO/probiotic overlap (Rao et al., 2018), a distinct clinical entity, not a default explanation for fatigue. Gut–brain signalling includes neural, endocrine, and immune routes; measurable permeability is more directly tied to immune and humoral mediators than to vagal pathways alone.

How barrier claims appear on consumer microbiome reports

Most direct-to-consumer stool panels do not assay permeability. Common indirect signals:

Report element	What it actually reflects	What it does not prove
Stool zonulin	ELISA signal of uncertain specificity	Gold-standard L:M ratio or segmental leak
Low Faecalibacterium / butyrate producers	Taxonomic abundance	Active barrier flux or mucus integrity
Akkermansia high or low	Mucin-associated ecology context	Simple good/bad barrier verdict, see species page
”Barrier pathway” metagenomic scores	Genetic potential in extracted DNA	Functional permeability
Dysbiosis / inflammation index	Vendor algorithm	Calprotectin-equivalent inflammation

Bundled calprotectin (where offered) measures neutrophilic inflammation, not leakiness directly, see Gut inflammation markers.

What tests may indicate barrier dysfunction?

Tier 1, closest to measuring permeability (research / specialist)

Test	What it measures	Notes
Lactulose–mannitol (L:M) urinary ratio	Small-intestinal paracellular permeability	Most used research standard; protocol heterogeneity (dose, timing) limits universal cut-offs
Multi-sugar probes (sucrose, rhamnose, sucralose, PEG)	Segment-specific or whole-gut permeability	Sucrose for proximal; sucralose/PEG for colonic leak in research
Ussing chamber / biopsy (research)	Ex vivo flux across mucosa	Not clinical routine

Tier 2, epithelial injury or inflammation (often more available clinically)

Test	Reflects	Not equivalent to
Fecal calprotectin	Neutrophilic intestinal inflammation	Permeability directly, see Calprotectin
Fecal lactoferrin	Inflammatory activity	Permeability
I-FABP (blood/urine)	Enterocyte damage (especially small intestine)	Chronic low-grade leak in functional disorders, mostly acute injury literature
Citrulline	Enterocyte mass/function	Barrier integrity proxy in specific settings

Tier 3, immune/translocation markers (research)

Marker	Interpretation limits
Plasma LPS, LBP, sCD14	Translocation + immune response; confounders abound
CRP, ESR	Systemic inflammation, non-specific
Celiac panel (TTG-IgA, etc.)	Autoimmune gluten enteropathy, treat cause, not “leaky gut” label

Tier 4, microbiome and consumer panels (indirect)

Signal	Possible relevance	Limits
Low Faecalibacterium / butyrate producers	Less SCFA support for colonocytes in theory	Does not measure flux
Akkermansia high/low	Mucus ecology context	Mucin degrader, dual interpretation
”Barrier pathway” metagenomic scores	Genetic potential only	Not functional permeability
Stool zonulin	Marketed as barrier marker	Same ELISA validation concerns as serum

What a sensible workup looks like (conceptual, not medical advice)

Red-flag symptoms → gastroenterology, not supplement protocols
Celiac serology if gluten-related symptoms or family history
Calprotectin if inflammatory diarrhoea suspected
Permeability testing only in research or specialist contexts where L:M is validated
Microbiome test for composition/context, not as permeability assay

Approaches discussed when barrier dysfunction is suspected (non-prescription)

Domain	Rationale in literature	Caveats
Treat underlying disease (celiac → GFD, IBD → medical care)	Only strategy with strong evidence for disease-linked leak	-
Adequate fermentable fiber / MACs	Supports mucus and SCFA ecology in models	See dietary fiber paradox if symptoms flare
Gluten exclusion	Essential in celiac; trial in NCGWS only with dietitian guidance	Do not skip celiac testing while on GFD
Limit unnecessary NSAIDs / alcohol	Known mucosal injury in some contexts	Individual risk
Probiotics	Strain-specific barrier effects in some IBS in vitro/animal studies; human data mixed	Not a permeability cure-all